Sorrento Therapeutics Inc (NASDAQ: SRNE) and INMEGEN (National Institute of Genomic Medicine Have Agreed to Collaborate for the Rapid Development of COVID-19 Therapeutics, Diagnostics, and Multivalent Coronavirus Vaccines

Sorrento Therapeutics Inc (NASDAQ: SRNE) has a subsidiary known as Sorrento Therapeutic Mexico that has agreed with INMGEN to collaborate in the testing, support, and development of several Covid-19 related medical products to be commercialized in Mexico. In addition, both INMEGEN and Sorrento Mexico will expand their cooperation efforts to include the addition of Sorrento-based Covid-19 pipeline medical products spanning multivalent vaccines, diagnostics, and therapeutics.

Some of the product candidates include; COVITRACK (an antibody diagnostic detection test designed for people with the vaccine), COVI-AMG (a neutralizing matured affinity antibody designed for outpatient Covid-19 patients), COVIDROPS (a neutralizing intranasal antibody of COVI-AMG designed for newly diagnosed patients), and COVISHIELD (a neutralizing antibodies cocktail designed to help harsh Sars-CoV-2 variants)

Sorrento Inc will provide a one-stop-shop of various solutions and an incredibly extensive portfolio to governments and nations that want to use the “detect and treat model” to fight the coronavirus. Sorrento Mexico intends to create local medical research and development functionalities within INMGEN’s personnel and facilities in Mexico. In addition, the company will work hand-in-hand with clinical institutions and hospitals in Mexico on approval requirements, regulatory registration, and clinical protocols for Covid-related medical products.

Senior Management

Sorrento Therapeutics’ Chief Executive Officer and Chairman, Henry Ji, Ph.D., said that they were delighted to be working with INMGEN and intend to make Sorrento Mexico a gateway to all the countries in South America for their innovative therapeutic, vaccine, and diagnostic candidates.

The company’s commitment to developing life-enhancing therapeutics is also seen by its effort to advance its non-opioid first-in-class pain management resiniferatoxin, and SP-102. The RTX product has gone through a Phase I clinical trial for untraceable pain linked to cancer. SEMEXDA, on the other hand, is in Phase III clinical trial for treating radicular pain or lumbosacral.